US FDA Authorize UCB’s Fintepla to Treat Rare Epilepsy in Children
The Food and Drug Administration (FDA) of the United States has now authorized Fintepla (fenfluramine) oral solution CIV developed by UCB for the purpose of treating the children above two years of age who are having seizures associated with Lennox-Gastaut Syndrome (LGS), which has been a rare form of epilepsy during the childhood. The regulator […]
Continue Reading